CapWealth Advisors LLC Acquires 310 Shares of Stryker Co. (SYK)

CapWealth Advisors LLC boosted its position in shares of Stryker Co. (NYSE:SYK) by 0.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,753 shares of the medical technology company’s stock after purchasing an additional 310 shares during the period. CapWealth Advisors LLC’s holdings in Stryker were worth $6,882,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in Stryker by 2.7% during the 2nd quarter. BlackRock Inc. now owns 24,551,677 shares of the medical technology company’s stock worth $4,145,795,000 after acquiring an additional 646,505 shares in the last quarter. FMR LLC grew its holdings in Stryker by 24.0% during the 2nd quarter. FMR LLC now owns 5,327,862 shares of the medical technology company’s stock worth $899,662,000 after acquiring an additional 1,032,333 shares in the last quarter. Morgan Stanley grew its holdings in Stryker by 7.3% during the 2nd quarter. Morgan Stanley now owns 2,305,235 shares of the medical technology company’s stock worth $389,262,000 after acquiring an additional 157,400 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Stryker by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 2,037,752 shares of the medical technology company’s stock worth $344,094,000 after acquiring an additional 63,251 shares in the last quarter. Finally, Carmignac Gestion grew its holdings in Stryker by 36.6% during the 1st quarter. Carmignac Gestion now owns 1,599,867 shares of the medical technology company’s stock worth $257,451,000 after acquiring an additional 428,789 shares in the last quarter. 75.11% of the stock is owned by institutional investors and hedge funds.

In related news, VP Katherine Ann Owen sold 37,866 shares of Stryker stock in a transaction dated Wednesday, September 5th. The shares were sold at an average price of $166.84, for a total value of $6,317,563.44. Following the sale, the vice president now directly owns 11,367 shares in the company, valued at approximately $1,896,470.28. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 750 shares of Stryker stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $178.17, for a total transaction of $133,627.50. Following the completion of the sale, the chief financial officer now owns 2,785 shares in the company, valued at $496,203.45. The disclosure for this sale can be found here. Company insiders own 7.30% of the company’s stock.

Several research analysts have weighed in on SYK shares. ValuEngine raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a report on Tuesday, September 11th. Canaccord Genuity reissued a “buy” rating and set a $185.00 price objective on shares of Stryker in a report on Wednesday, July 25th. Royal Bank of Canada reissued a “buy” rating and set a $184.00 price objective on shares of Stryker in a report on Wednesday, July 25th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $170.00 price objective on shares of Stryker in a report on Wednesday, June 13th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $178.33.

Stryker stock opened at $175.00 on Tuesday. The stock has a market capitalization of $66.45 billion, a PE ratio of 26.96, a price-to-earnings-growth ratio of 2.49 and a beta of 0.59. Stryker Co. has a 1 year low of $143.55 and a 1 year high of $179.84. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.15 and a current ratio of 1.83.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 24th. The medical technology company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.03. The firm had revenue of $3.32 billion for the quarter, compared to the consensus estimate of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. Stryker’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.53 EPS. On average, research analysts expect that Stryker Co. will post 7.25 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Investors of record on Friday, September 28th will be given a $0.47 dividend. The ex-dividend date of this dividend is Thursday, September 27th. This represents a $1.88 annualized dividend and a yield of 1.07%. Stryker’s dividend payout ratio is presently 28.97%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Article: How Do Tariffs Affect Trade Balances?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply